DRUG NAME: Eribulin - BC Cancer
(SCNAUSEA) Guidelines for Prevention and Treatment of Chemotherapy-induced Nausea and Vomiting in Adults. Vancouver, British Columbia: BC Cancer Agency; 1 Mar 2012. 7. BC Cancer Agency Breast Tumour Group. (UBRAVERIB) BCCA Protocol Summary for Palliative Therapy for Metastatic Breast
Download DRUG NAME: Eribulin - BC Cancer
Information
Domain:
Source:
Link to this page:
Documents from same domain
Oncology Nutrition High Protein High Energy …
www.bccancer.bc.caHigh Protein High Energy Food Choices 3 Examples of High Protein Foods • All meat (eg. beef, pork, goat, lamb) • Fish and shellfish • All poultry (eg. chicken, turkey, duck)
BC CANCER HAZARDOUS DRUG LIST
www.bccancer.bc.caBC CANCER HAZARDOUS DRUG LIST (Refer to: Pharmacy Directive VI-80 Hazardous Drug List) The BC Cancer Hazardous Drug List (BC Cancer HD List) is comprised of:
Safe Handling of Hazardous Drugs - BC Cancer
www.bccancer.bc.caA.1 Potential Hazards of Handling Hazardous Drugs..... 1 A.2 Hazardous Drug List.....
“Magic” mouthwash explained - BC Cancer
www.bccancer.bc.caFAMILY PRACTICE ONCOLOGY NETWORK JOURNAL / FALL 2014 3 “Magic” mouthwash explained By Dr. Allan Hovan, Provincial Professional Practice Leader,
Symptom Management Guidelines: ORAL …
www.bccancer.bc.caSymptom Management Guidelines: ORAL MUCOSITIS . Definition Oral Mucositis (Stomatitis): An acute inflammation and/or ulceration of the …
Guidelines for Management of CID - BC Cancer
www.bccancer.bc.caDisclaimer Both the format and content of the guidelines will change as they are reviewed and revised on a periodic basis. Any physician using these guidelines to provide
British Columbia Cancer Agency POLICY
www.bccancer.bc.caBritish Columbia Cancer Agency ¦ POLICY Title: PREVENTION AND MANAGEMENT OF EXTRAVASATION OF CHEMOTHERAPY Number: III-20 Effective Date: Provincial Systemic Program September 1,1997
Symptom Management Guidelines: FEVER AND …
www.bccancer.bc.caSymptom Management Guidelines: FEVER AND NEUTROPENIA . Definition • Fever: A single oral temperature of ≥ 38.3° C (101° F) OR a temperature ≥ 38 ° C (100.4 ° F) which lasts more than 1h
Symptom Management Guidelines: XEROSTOMIA
www.bccancer.bc.caSymptom Management Guidelines: XEROSTOMIA. Definition(s) • Xerostomia: abnormal dryness in the mouth characterized by a marked decrease and/or thickening of saliva, may be
Linking the BC Psychosocial Community Oncology …
www.bccancer.bc.caCarolyn Jacob - New Regional Professional Practice Leader at the Centre for the North. We welcome Carolyn Jacob, MSW, RSW to her new role at the BC
Related documents
DRUG NAME: Carboplatin - BC Cancer
www.bccancer.bc.caCarboplatin Myelosuppression is the dose-limiting toxicity, usually manifested as thrombocytopenia and less commonly as leukopenia, neutropenia and anemia. Risk factors include prior cytotoxic therapy (especially cisplatin), poor performance status, old age, impaired renal function and concurrent myelosuppressive therapy.
Symptom Management Guidelines: Nausea and Vomiting
www.bccancer.bc.caAny unnecessary medications contributing to nausea and vomiting should be discontinued (in consultation with physician and pharmacist) Select anti-nausea medication based on the cause of the nausea and vomiting, See . Appendix B Examples: High Risk Chemotherapy induced: add Aprepitant. Cannabis for refractory Opioid-induced nausea
Dental treatment considerations in the chemotherapy patient
www.medicinaoral.comHueso et al. Chemotherapy-induced acral erythema: a clinical and histopathologic study of 44 cases Actas Dermosifiliogr. 2008 Case series Boonyapakorn et al. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 2008 Cohort Jensen et al.
ZOFRAN (ondansetron hydrochloride) Label
www.accessdata.fda.govabdominal surgery or chemotherapy-induced nausea and vomiting Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction. (5.4) • Phenylketonuric patients should be informed that ZOFRAN ODT orally disintegrating tablets contain phenylalanine (a component of aspartame).
DRUG NAME: Oxaliplatin
www.bccancer.bc.ca(grades 3-4) diarrhea, nausea and vomiting, and neurotoxicity are more common with combination ... do not appear to reduce or protect against oxaliplat in-induced neurotoxicity. 49-52. ... Chemotherapy Preparation and Stability Chart in Appendix.
DRUG NAME: Palbociclib - BC Cancer
www.bccancer.bc.ca11. BC Cancer Agency. (SCNAUSEA) Guidelines for Prevention and Treatment of Chemotherapy-induced Nausea and Vomiting in Adults. Vancouver, British Columbia: BC Cancer Agency; 1 Mar 2012. 12. Pfizer Canada Inc. IBRANCE® product monograph. Kirkland, Quebec; 24 January 2020. 13. BC Cancer Breast Tumour Group.
Guidelines for Prevention and Treatment of Chemotherapy ...
www.bccancer.bc.caChemotherapy-Induced Nausea and Vomiting in Adults . Protocol Code . SCNAUSEA : Tumour group : SUPPORTIVE CARE . Physician Contact . Dr. Wendie den Brok . ELIGIBILITY • Adults receiving chemotherapy. • Drug acquisition: Antiemetics are considered supportive treatment. These agents are not BC
Relaxation Techniques - National Institutes of Health
files.nccih.nih.govMay 31, 2016 · chemotherapy-induced nausea, and . temporomandibular joint dysfunction. Psychological therapies, which may include relaxation techniques, can help manage . chronic headaches and other types of chronic pain in children and adolescents. Relaxation techniques have also been studied for other conditions,
HIGHLIGHTS OF PRESCRIBING INFORMATION See Full …
www.accessdata.fda.govchemotherapy-induced nausea and vomiting is recommended. ( 2.2) •Monitor patients during the infusion and for at least 30 minutes after completion of infusion. Treatment interruption and/or dose reduction may be needed to manage adverse reactions. (2.2) •See Full Prescribing Information for preparation and administration instructions. (2.4)
The Benefits of Marijuana Legalization and Regulation
www.bjcl.orgOromucosal Standardized Cannabis Extract in Chemotherapy-induced Nausea and Vomiting, 70 J. OF CLINICAL PHARMACOLOGY 656 (2010); M. Earleywine & S.S. Barnwell, Decreased Respiratory Symptoms in Cannabis Users Who Vaporize, 4 HARM REDUCTION J. (2007); M. Earleywine et al., Case studies in cannabis vaporization, 18 ADDICTION RES.